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The N-Methyl-D-Aspartate Antagonist CNS 1102 Protects
Cerebral Gray and White Matter From Ischemic Injury
Following Temporary Focal Ischemia in Rats
Wolf-R. Scha¨bitz, MD; Fuhai Li, MD; Marc Fisher, MD
Background and Purpose—Cerebral white matter is as sensitive as gray matter to ischemic injury and is probably
amenable to pharmacological intervention. In this study we investigated whether an N-methyl-D-aspartate (NMDA)
antagonist, CNS 1102, protects not only cerebral gray matter but also white matter from ischemic injury.
Methods—Ten rats underwent 15 minutes of temporary focal ischemia and were blindly assigned to CNS 1102 intravenous
bolus injection (1.13 mg/kg) followed by intravenous infusion (0.33 mg/kg per hour) for 3.75 hours or to vehicle (n55
per group) immediately after reperfusion. Seventy-two hours after ischemia, the animals were perfusion fixed for
histology. The severity of neuronal necrosis in the cortex and striatum was semiquantitatively analyzed. The Luxol fast
blue–periodic acid Schiff stain and Bielschowsky’s silver stain were used to measure optical densities (ODs) of myelin
and axons, respectively, in the internal capsule of both hemispheres, and the OD ratio was calculated to reflect the
severity of white matter damage.
Results—Neuronal damage in both the cortex and the striatum was significantly better in the drug-treated group than in
the placebo group (P,0.05). The OD ratio of both the axons (0.9360.08 versus 0.6160.18; P,0.01) and the myelin
sheath (0.9560.07 versus 0.6760.19; P50.01) was significantly higher in the CNS 1102 group than in the placebo
group. The neurological score was significantly improved in the drug-treated group (P,0.05).
Conclusions—The NMDA receptor antagonist CNS 1102 protects not only cerebral gray matter but also white matter from
ischemic injury, most probably by preventing degeneration of white matter structures such as myelin and axons. (Stroke.
2000;31:1709-1714.)
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Acute central nervous system injuries such as ischemicstroke are accompanied by a marked elevation in the
extracellular glutamate concentration.1 Toxic activation of
glutamate receptors, or excitotoxicity, is an important trigger
of neuronal death.2 Glutamate-triggered Ca21 influx can be
specifically blocked by antagonists of the receptor-mediated,
Ca21-conducting N-methyl-D-aspartate (NMDA) channels
that are predominantly on neurons. NMDA receptor antago-
nists such as MK 801 or CNS 1102 (Cerestat) protect gray
matter from ischemic injury.3–6 Cerebral white matter was
shown to be sensitive to acute ischemia and can probably be
protected by pharmacological intervention.7 In contrast to
gray matter, glutamate is not thought to play an important role
in white matter ischemic injury.8,9 As suggested by in vitro
studies, Ca21 overload in ischemic axons is related to activa-
tion of Na1 channels rather than a function of a glutamate
receptor stimulation.9 Clinically, it is important to understand
and treat white matter ischemic changes that are common in
the elderly. To our knowledge, no in vivo studies exist
concerning pharmacological protection of cerebral white
See Editorial Comment, page 1714
matter changes after cerebral ischemia. In this study we
investigated whether pharmacological intervention with a
potent neuroprotectant, the noncompetitive NMDA antago-
nist CNS 1102, could be used to protect white matter
structures after focal cerebral ischemia.
Materials and Methods
All procedures were approved by our institutional Animal Research
Committee. In 10 male Sprague-Dawley rats weighing 300 to 350 g,
15 minutes of temporary focal cerebral ischemia was induced by the
intraluminal suture occlusion method. All experiments were per-
formed in a blinded manner. Nonfasted animals were randomly
assigned before surgery to receive CNS 1102 dissolved in saline
(n55) or the same amount of vehicle (n55).
The animals were intraperitoneally anesthetized with chloral
hydrate (400 mg/kg body wt). The left femoral artery was cannulated
with PE-50 polyethylene tubing for continuous monitoring of arterial
blood pressure and blood sampling for analysis of blood gases.
Measurements were recorded before surgery and 30 and 180 minutes
after ischemic onset. Rectal temperature was maintained during
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surgery at 37°C with a feedback-regulated heating lamp. The right
middle cerebral artery was occluded via a transvascular approach, as
previously described.10,11 Briefly, the right common carotid artery
and the right external carotid artery were exposed through a midline
neck incision. The proximal portions of the common carotid artery
and the external carotid artery were first ligated with a 3-0 silk
suture. A 4-0 monofilament nylon suture (length 40 mm), whose tip
had been rounded by heating near a flame and then coated with
silicon (Bayer), was inserted through an arteriectomy of the common
carotid artery and gently advanced into the internal carotid artery.
Positioned approximately 17 mm from the bifurcation, the tip of the
suture occludes the proximal anterior cerebral artery, the origins of
the middle cerebral artery, and the posterior communicating artery.
To prevent bleeding, the common carotid artery was loosely ligated
with a 3-0 silk suture just distal to the arteriotomy.
An intravenous bolus injection of the drug (1.13 mg/kg in saline)
or the vehicle (saline) was started immediately after reperfusion (15
minutes after vessel occlusion), followed by a continuously intrave-
nous infusion for 3.75 hours at a dose of 0.33 mg/kg per hour of CNS
1102 or physiological saline. CNS 1102 has a half-life of 63 minutes,
is lipophilic, and easily crosses the blood-brain barrier, like most
other noncompetitive NMDA antagonists.4 The chemical structure of
CNS 1102 was reported in a previous study.4 After discontinuation
of the infusion, the animals were allowed to recover from the
anesthesia and were neurologically scored with a 5-point scale: 0, no
neurological deficit; 1, failure to extent left forepaw fully; 2, circling
to the left; 3, falling to the left; and 4, no spontaneous walking with
a depressed level of consciousness.
Over the next 3 days the animals had free access to food and
water. The neurological examination was performed daily in all
animals. On the fourth day the animals were anesthetized again with
chloral hydrate and transcardially perfusion fixed with 4% parafor-
maldehyde in 0.1 mmol/L phosphate buffer for histological and
immunohistochemical studies. The heads were decapitated and were
allowed to fix overnight in 4% paraformaldehyde. On the next day,
the brains were removed from the skull and immersed again in the
same fixative solution at 4°C. Each brain was then sectioned into 5
coronal slices of 2-mm slice thickness. These were labeled A
(frontal) through E (occipital). Histology sections (approximately
6 mm thick) were obtained from the paraffin blocks and stained with
hematoxylin and eosin (H&E), Luxol fast blue–periodic acid Schiff
(LFB-PAS), Bielschowsky’s silver impregnation, and glial fibrillary
acidic protein (GFAP). The pathological assessments were per-
formed by observers blinded to the treatment groups.
For the study of the white matter, 1 slice at the level of the anterior
commissure was selected.7 The LFB-PAS and Bielschowsky’s silver
stains were used to measure optical densities (ODs) of myelin
(LFB-PAS) and axons (Bielschowsky’s stain) in the ipsilateral
internal capsule and contralateral homologous area. The measured
OD values reflect the stainability of white matter, and a decreased
OD value indirectly reflects destruction of white matter because of
loss of stainability. The OD measurement was previously used to
evaluate the activity of glial cells.12 Measurements were made on
images collected with a video-imaging microscope system with the
use of a computerized cytomorphometric analysis (Global Labora-
tory Analysis System). At a magnification of 320, the ODs of 10
nonoverlapping areas of 5000 mm2 were measured from each side of
the brain in the same corresponding area. The OD ratio in myelin and
axons was calculated by dividing the ipsilateral OD by the contralat-
eral OD. For quantification of neuronal damage, H&E stain was used
to evaluate neuronal necrosis in the striatum and cortex with a
5-point scale: 0, no neuronal necrosis; 1, individual neuronal
necrosis; 2, selective neuronal necrosis (SNN); 3, widespread neu-
ronal necrosis; and 4, pannecrosis. GFAP staining was used to
evaluate changes of glial cells.
After acquisition of all data, the randomization code was broken.
Data were presented as mean6SD. One-factor ANOVA was used to
compare physiological variables. White matter data (OD ratio) were
compared between the 2 groups with an unpaired 2-tailed t test. A
Mann-Whitney U test corrected for ties was performed for nonpara-
metric variables (neurological score and gray matter data). A P value
,0.05 was considered statistically significant.
Results
Physiological variables, presented in the Table, showed no
significant differences between the 2 groups (P.0.05). The
percent body weight decline did not differ between the 2
groups (15.3% versus 13.4%). The neurological score at day
4 was significantly worse in the placebo than in the CNS
1102–treated group (1.060.5 versus 0.460.3; P,0.05).
The histopathological analysis revealed that 3 of the 5 rats
in the placebo group had widespread neuronal necrosis in
both the cortex and striatum, and 2 other rats had SNN in the
striatum and individual neuronal necrosis or SNN in the
frontoparietal cortex. These changes were accompanied by
Figure 1. Neuronal cell damage in the striatum and cortex after
15 minutes of transient ischemia followed by 72 hours of reper-
fusion in the CNS 1102–treated group and placebo group
(*P,0.05, Mann-Whitney U test).





PCO2, mm Hg 45610 4663
PO2, mm Hg 75613 7466
MABP, mm Hg 6465 6467
Body temperature, °C 36.360.6 36.660.5
30 min after MCAO
pH 7.3560.03 7.3360.04
PCO2, mm Hg 4565 4667
PO2, mm Hg 71612 71614
MABP, mm Hg 70614 68611
Body temperature, °C 37.160.2 36.960.3
180 min after MCAO
pH 7.3460.03 7.3460.02
PCO2, mm Hg 4265 4264
PO2, mm Hg 7867 82611
MABP, mm Hg 78610 7868
Body temperature, °C 37.160.2 37.060.2
Data are mean6SD. MABP indicates mean arterial blood pressure; MCAO,
middle cerebral artery occlusion. Differences between groups in each variable
were not statistically significant (P.0.05, 1-factor ANOVA).
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astrogliosis and microglia activation. In the CNS 1102–
treated rats, 2 rats showed normal cerebral gray matter, 1 had
individual neuronal necrosis only in the striatum, and 2 other
animals demonstrated SNN in the striatum and individual
neuronal death in the cortex. Overall statistical analysis
revealed that both cortical and striatal neuronal damage in the
CNS 1102–treated group were significantly better than in the
placebo group (P,0.05), as shown in Figure 1.
Representative photomicrographs chosen from the internal
capsule from both groups are shown in Figure 2. White matter
in the 2 control animals that had SNN in the gray matter
appeared vacuolized. The myelin sheaths and axons were
moderately damaged. A moderate astrocytic reaction with
increased GFAP immunoreactivity and a few microglia oc-
curred in the same area. Oligodendrocytes proliferated in the
periphery of the white matter lesion. Three other animals in
the control group that had severe ischemic lesions also
developed severe white matter damage. Myelin sheaths lost
their LFB-PAS stainability and appeared as empty spaces
(vacuoles) separating myelin sheaths in the lesion areas of
white matter (Figure 2B and 2E). Axons appeared as irregu-
lar, twisted profiles and showed segmental fragmentation
with Bielschowsky’s stain (Figure 2H). Increased cellular
reactions occurred in the injured white matter that included
inflammatory cells, in particular macrophages. Hypertrophied
astrocytes with strong GFAP immunoreactivity and activated
microglia were found in the lesion area. In the CNS 1102–
treated group, 3 rats with essentially normal gray matter
revealed no substantial damage to white matter. The 2 other
animals with mild gray matter injury had mild vacuolization
and mild damage of myelin sheaths with moderate astrocytic
and microglial reactions (Figure 2C and 2F). Axons were well
preserved (Figure 2I). Overall statistical analysis demon-
strated that axonal injury in cerebral white matter (OD ratio:
0.9360.08 in the CNS 1102–treated group versus 0.6160.18
in the placebo group; P,0.01) and damage to the myelin
sheath (OD ratio: 0.9560.07 in the CNS 1102–treated group
versus 0.6760.19 in the placebo group; P50.01) was signif-
icantly reduced by CNS 1102 treatment (Figure 3).
Discussion
This study demonstrates that a noncompetitive NMDA recep-
tor antagonist, CNS 1102, protects cortical and striatal neu-
rons from ischemic injury and significantly reduces ischemic
damage in white matter structures such as myelin and axons.
This qualitative observation of reduced white matter injury
should, in the future, be confirmed by a more quantitative
approach such as a Western blot analysis of axonal and
myelin injury. Clinically, CNS 1102 improved the neurolog-
ical outcome. No significant difference in physiological
parameters and weight loss was observed between the 2
groups during the experiment as it has been reported by other
investigators.4,5
Cerebral ischemia triggers an excessive release of gluta-
mate, producing overstimulation of glutamate receptors, es-
pecially the NMDA receptor. The subsequent cellular Ca21
overload is generally thought to represent the “final common
pathway,” leading to necrotic cell death of neurons.13 NMDA
antagonists that prevent the Ca21 influx through NMDA
receptor blockade of Ca21 channels have successfully been
used to treat neuronal injury after experimental ischemia in
vivo.3– 6 CNS 1102 (Cerestat) in particular is a well-
investigated NMDA antagonist that has potent neuroprotec-
tive effects.6 CNS 1102 in this study protected striatal and
cortical neurons from temporary focal cerebral ischemia.
Similar results have been reported on ischemic lesion size
with the use of the same dose after permanent and temporary
focal cerebral ischemia.4,5
The main novel finding in this study is that CNS 1102
protects white matter structures such as axons and myelin
from ischemic injury. This finding is of importance because it
demonstrates that white matter damage after ischemia may be
treatable and could be of particular clinical interest for the
future treatment of lacunar strokes. Although studies have
demonstrated that white matter is susceptible to ischemic
injury, the mechanisms of white matter injury are not well
characterized.7,14 In contrast to gray matter ischemia, in vitro
studies suggest that activation of glutamate receptors may not
be a key event in the mediation of ischemic cerebral white
matter injury. Recent studies suggested some possible expla-
nations for ischemic white matter injury.8 First, the Na1,K1-
ATPase of CNS axons fails after ischemia, leading to accu-
mulation of axoplasmatic Na1 through noninactivating Na1
channels. Coupled with severe K1 depletion that results in
large membrane depolarization, high intracellular Na1 stim-
ulates the reverse operation of Na1-Ca21 exchanger, causing
axonal Ca21 overload that results in white matter injury by
activating Ca21-dependent enzymes.8,9 Accumulation of in-
tracellular Ca21 and subsequent damage to the myelin sheath
can also occur through reversal of the electrogenic Na1,K1-
glutamate transporter after axonal depolarization.8,15 Second,
oligodendrocytes that myelinate the axon can be damaged in
vitro by glutamate exposure, which does not appear to
involve glutamate receptor activation.16 Third, a-amino-3-
hydroxy-5-methyl-4-isoxasole propionic acid (AMPA)/kai-
nate seems to be more toxic to oligodendrocytes. It has been
shown that oligodendrocytes contain the AMPA receptor and
can be damaged in vivo by AMPA or kainate.17 Lastly,
degeneration secondary to gray matter damage, so-called
wallerian degeneration, may be another important contributor
to white matter injury. Excitotoxic lesions in the thalamus or
basal ganglia have been shown experimentally to secondarily
damage white matter structures such as the myelin and axon
within 2 to 4 days.18 White matter damage observed in the
present study may be related to wallerian degeneration
because survival time in our study was within this time frame
(3 days), and the gray matter lesion was primarily in the
striatum with selective neuronal necrosis in the cortex.
On the basis of the mechanisms of white matter injury
described above, protection of white matter from ischemic
injury may be obtained by blocking Na1 channel,8 reducing
Ca21 load,8 inhibiting AMPA receptors,8,17 or protecting gray
matter.8 The protective effect of ketamine, an NMDA recep-
tor antagonist, on anoxic optic nerve was previously reported
and was supposed to be related to its blocking voltage-gated
Na1 channels.19 Interestingly, an NMDA receptor antagonist
was demonstrated to protect the spinal cord from ischemic
injury.20 It is not known whether the NMDA antagonist
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exerted its action on spinal gray matter or white matter.8 It
seems unlikely that the protective affect of NMDA receptor
antagonists on white matter is mediated by direct NMDA
receptor, since neither the axon nor the myelin has been
proven to contain NMDA receptors. The most plausible
mechanism of the neuroprotective effect of CNS 1102 in the
present study is likely a secondary prevention of white matter
damage by neuroprotection of cerebral gray matter. Clearly,
further studies will be needed to elucidate how NMDA
receptor antagonists protect white matter from ischemic
injury.
In this study white matter damage was induced with the
intraluminal suture occlusion model. The short occlusion time
was chosen to provide demonstrable white matter damage, to
keep gray matter damage minimal, and to guarantee a long
survival time. However, to further understand white matter
damage in vivo and to explore how drugs protect white matter
in vivo, an animal model of pure white matter ischemia would
be useful. This is thus far not available for both technical and
pathophysiological reasons.
In conclusion, the present study suggests that besides the
previously known protective effects of this NMDA antagonist,
additional protection of white matter structures such as myelin
and axons after focal cerebral ischemia does occur. The role of
NMDA antagonists in protecting white matter from ischemic
injury needs further clarification. The study of in vivo white
matter injury after focal ischemia is of particular clinical rele-
vance because of the prevalence of lacunar strokes.
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Figure 2. Representative photomicrographs from the internal capsule showing histopathological changes of cerebral white matter after 15
minutes of transient ischemia followed by 72 hours of reperfusion in both CNS 1102–treated and placebo-treated animals. A through C, H&E
stain (magnification 3160). A, Normal white matter in the nonischemic contralateral hemisphere. B, Vacuolization (arrowheads) and increased
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1102–treated animal (ischemic side). Note moderately enlarged astrocytic nucleus (arrowhead). D through F, LFB-PAS stain (magnification
320). D, Normal myelin sheaths in the nonischemic contralateral white matter (blue color, arrowheads). E, Myelin sheaths that were broken
into fragments with vacuoles showed less LFB-PAS stainability in a placebo-treated rat (arrowheads). F, Better-preserved myelin in a CNS
1102–treated animal (arrowheads). G through I, Bielschowsky’s silver stain impregnation (magnification 320). G, Normal axons in nonische-
mic contralateral white matter organized in bundles (dark color, arrowheads). H, Irregular twisted axons with segmental fragmentation showed
less stainability in a placebo-treated animal (arrowheads). I, Better-preserved axons in a CNS 1102–treated animal (arrowheads).
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Editorial Comment
During the past 2 decades, basic and preclinical studies have
demonstrated the significant involvement of glutamate neu-
rotoxicity in neuronal death and infarction after cerebral
ischemia. Despite this understanding, clinical trials that used
neuroprotective agents which targeted glutamate neurotoxic-
ity and other biochemical cascades involved in neuronal
death have failed.1 It is suggested that alternative and/or new
therapeutic strategies are needed. One possible strategy is to
protect white matter from ischemic injury. In this article,
Scha¨bitz and colleagues have provided intriguing results
which demonstrate that an NMDA antagonist protects both
cerebral gray and white matter from ischemic injury after
temporary focal ischemia in rats. This is a somewhat surpris-
ing but novel finding, since it is known that the axons and
myelin sheaths may not contain NMDA receptors. Neverthe-
less, the authors have provided some plausible explanations
for their observations. Because white matter oligodendrocytes
are known to be vulnerable to AMPA/kainate receptor–
mediated excitotoxicity,2 the possible AMPA/kainate recep-
tor agonist property of this drug needs further evaluation.
This study provides an impetus for additional therapeutic
studies that will target the white matter after transient focal
cerebral ischemia.3
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